Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus - PubMed (original) (raw)
Comparative Study
doi: 10.1111/pedi.12167. Epub 2014 Jul 11.
Affiliations
- PMID: 25039448
- DOI: 10.1111/pedi.12167
Comparative Study
Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus
Saygın Abalı et al. Pediatr Diabetes. 2015 Aug.
Abstract
Objective: We aimed to compare hemoglobin A1c (HbA1c), total and basal insulin doses, basal insulin injection frequencies, and body mass index (BMI) in children with type 1 diabetes mellitus (T1DM) who are receiving detemir and glargine as basal insulin in a basal-bolus therapy.
Method: This retrospective study included 117 (53 females) children and adolescents with T1DM older than 4 yr of age, minimum diabetes duration of 2 yr, and receiving basal-bolus insulin regimen (at least 4 injections/d, insulin aspart or lispro as bolus insulin). Comparisons were made for those receiving insulin detemir (n = 32) or glargine (n = 85) as the basal insulin.
Results: Age, pubertal status, BMI standard deviation scores, and diabetes duration were similar in detemir and glargine groups. Glycemic control was similar in both groups (HbA1c levels 8.9 ± 2.1% vs. 8.5 ± 1.7% for detemir and glargine, respectively; p = 0.497). Both mean basal insulin (0.52 vs. 0.41 U/kg/d, p < 0.001) and mean total daily insulin (1.11 vs. 0.93 U/kg/d, p < 0.001) doses were higher in the detemir group. Furthermore, higher ratio of twice-daily basal insulin injection was detected in the detemir group (62.5 vs. 32.9% p = 0.004). Subgroup analysis according to pubertal status, or the number of daily basal injections showed similar results.
Conclusion: Insulin detemir provides similar glycemic control with glargine, but, approximately 27% higher mean basal and 19% higher mean total insulin doses with two-fold more twice-daily basal insulin injection requirement.
Keywords: HbA1c; T1D; children; detemir; glargine.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
- Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S, Koenen C, Bode B. Heller S, et al. Clin Ther. 2009 Oct;31(10):2086-97. doi: 10.1016/j.clinthera.2009.10.006. Clin Ther. 2009. PMID: 19922879 Clinical Trial. - Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S, Facchinetti A, Bonora BM, Mariano V, Boscari F, Cipponeri E, Maran A, Avogaro A, Fadini GP, Bruttomesso D. Galasso S, et al. Nutr Metab Cardiovasc Dis. 2016 Dec;26(12):1112-1119. doi: 10.1016/j.numecd.2016.08.002. Epub 2016 Aug 6. Nutr Metab Cardiovasc Dis. 2016. PMID: 27618501 - Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
Rautiainen P, Tirkkonen H, Laatikainen T. Rautiainen P, et al. Diabetes Technol Ther. 2018 May;20(5):363-369. doi: 10.1089/dia.2018.0027. Epub 2018 May 9. Diabetes Technol Ther. 2018. PMID: 29741925 - Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?
Wallace JP, Wallace JL, McFarland MS. Wallace JP, et al. Ann Pharmacother. 2014 Mar;48(3):361-8. doi: 10.1177/1060028013518420. Epub 2014 Jan 6. Ann Pharmacother. 2014. PMID: 24396092 Review. - Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
Dailey G, Admane K, Mercier F, Owens D. Dailey G, et al. Diabetes Technol Ther. 2010 Dec;12(12):1019-27. doi: 10.1089/dia.2010.0063. Diabetes Technol Ther. 2010. PMID: 21128849 Free PMC article. Review.
Cited by
- Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades.
Saboo B, Chandalia H, Ghosh S, Kesavadev J, Kochar IPS, Prasannakumar KM, Sarda A, Bantwal G, Mehrotra RN, Rai M. Saboo B, et al. Curr Diabetes Rev. 2024;20(1):e100323214554. doi: 10.2174/1573399819666230310150905. Curr Diabetes Rev. 2024. PMID: 36896906 Free PMC article. Review. - Differences of FreeStyle Libre Flash Glucose Monitoring System and Finger Pricks on Clinical Characteristics and Glucose Monitoring Satisfactions in Type 1 Diabetes Using Insulin Pump.
Al Hayek AA, Robert AA, Al Dawish MA. Al Hayek AA, et al. Clin Med Insights Endocrinol Diabetes. 2019 Jul 1;12:1179551419861102. doi: 10.1177/1179551419861102. eCollection 2019. Clin Med Insights Endocrinol Diabetes. 2019. PMID: 31308786 Free PMC article. - Effectiveness and safety of insulin glargine versus detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis.
Silva TBC, Almeida PHRF, Araújo VE, Acurcio FA, Guerra Júnior AA, Godman B, Alvares J. Silva TBC, et al. Ther Adv Endocrinol Metab. 2018 Jun 22;9(8):241-254. doi: 10.1177/2042018818781414. eCollection 2018. Ther Adv Endocrinol Metab. 2018. PMID: 30181850 Free PMC article. - Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
Vargas-Uricoechea H. Vargas-Uricoechea H. J Diabetes Res. 2018 Feb 12;2018:2052101. doi: 10.1155/2018/2052101. eCollection 2018. J Diabetes Res. 2018. PMID: 29619381 Free PMC article. Review. - rDNA insulin glargine U300 - a critical appraisal.
Wang F, Zassman S, Goldberg PA. Wang F, et al. Diabetes Metab Syndr Obes. 2016 Dec 2;9:425-441. doi: 10.2147/DMSO.S87873. eCollection 2016. Diabetes Metab Syndr Obes. 2016. PMID: 27980431 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical